ATE549342T1 - Rapamycinanaloge und deren verwendungen bei der behandlung proliferativer, entzündlicher und neurologischer störungen - Google Patents
Rapamycinanaloge und deren verwendungen bei der behandlung proliferativer, entzündlicher und neurologischer störungenInfo
- Publication number
- ATE549342T1 ATE549342T1 AT05849447T AT05849447T ATE549342T1 AT E549342 T1 ATE549342 T1 AT E549342T1 AT 05849447 T AT05849447 T AT 05849447T AT 05849447 T AT05849447 T AT 05849447T AT E549342 T1 ATE549342 T1 AT E549342T1
- Authority
- AT
- Austria
- Prior art keywords
- proliferative
- inflammatory
- treatment
- neurological disorders
- rapamycin analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63766604P | 2004-12-20 | 2004-12-20 | |
PCT/US2005/045551 WO2006068932A2 (en) | 2004-12-20 | 2005-12-15 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE549342T1 true ATE549342T1 (de) | 2012-03-15 |
Family
ID=36087657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05849447T ATE549342T1 (de) | 2004-12-20 | 2005-12-15 | Rapamycinanaloge und deren verwendungen bei der behandlung proliferativer, entzündlicher und neurologischer störungen |
Country Status (27)
Country | Link |
---|---|
US (5) | US7276498B2 (es) |
EP (1) | EP1828202B1 (es) |
JP (1) | JP5094406B2 (es) |
KR (1) | KR20070090913A (es) |
CN (1) | CN101084227B (es) |
AR (1) | AR052269A1 (es) |
AT (1) | ATE549342T1 (es) |
AU (1) | AU2005319454B2 (es) |
BR (1) | BRPI0519495A2 (es) |
CA (1) | CA2590155A1 (es) |
CR (1) | CR9148A (es) |
DK (1) | DK1828202T3 (es) |
ES (1) | ES2380779T3 (es) |
GT (1) | GT200500368A (es) |
HK (1) | HK1108442A1 (es) |
HN (1) | HN2005035605A (es) |
IL (1) | IL183664A (es) |
MX (1) | MX2007007408A (es) |
NI (1) | NI200700157A (es) |
NO (1) | NO20072664L (es) |
NZ (1) | NZ574663A (es) |
PE (1) | PE20060765A1 (es) |
RU (1) | RU2394036C2 (es) |
SG (1) | SG158143A1 (es) |
TW (1) | TW200628152A (es) |
UA (1) | UA94034C2 (es) |
WO (1) | WO2006068932A2 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101131794B1 (ko) * | 2002-07-30 | 2012-03-30 | 와이어쓰 엘엘씨 | Cci-779 공용매 농축액, 비경구 cci-779 제형 및 비경구 cci-779 제형의 제조방법 |
CA2556622A1 (en) * | 2004-03-02 | 2005-09-15 | Wyeth | Macrolides and methods for producing same |
CA2567043A1 (en) * | 2004-06-03 | 2005-12-22 | Wyeth | Biosynthetic gene cluster for the production of a complex polyketide |
MX2007007409A (es) * | 2004-12-20 | 2007-07-12 | Wyeth Corp | Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos. |
ES2380779T3 (es) * | 2004-12-20 | 2012-05-18 | Wyeth Llc | Análogos de rapamicina y usos de los mismos en el tratamiento de trastornos neurológicos, proliferativos e inflamatorios |
KR20080077618A (ko) * | 2005-12-07 | 2008-08-25 | 와이어쓰 | 정제된 결정체 cci-779 의 제조 방법 |
KR20080077147A (ko) * | 2005-12-07 | 2008-08-21 | 와이어쓰 | 결정성 라파마이신의 제조 방법 및 시차 주사 열량계를사용하는 라파마이신 화합물의 결정화도의 측정 방법 |
WO2007067560A2 (en) * | 2005-12-07 | 2007-06-14 | Wyeth | Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate |
CA2643350A1 (en) * | 2006-03-07 | 2007-09-13 | Wyeth | Meridamycin analogues for the treatment of neurodegenerative disorders |
US20100081681A1 (en) * | 2006-08-16 | 2010-04-01 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
CA2676613A1 (en) * | 2007-01-29 | 2008-08-07 | Wyeth | Immunophilin ligands and methods for modulating immunophilin and calcium channel activity |
JP2008305262A (ja) * | 2007-06-08 | 2008-12-18 | Konica Minolta Business Technologies Inc | サーバ及びシンクライアント環境でのプリンタ紹介方法 |
EP2205249B1 (en) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
US8653045B2 (en) * | 2008-02-05 | 2014-02-18 | The Johns Hopkins University | Induction of thyroid iodide-handling gene expression in human cancers |
US20090209527A1 (en) * | 2008-02-19 | 2009-08-20 | Wyeth | Methods for Using Rapamycin Analogues in the Treatment of Neurological Disorders |
CA2743491C (en) | 2008-11-11 | 2016-10-11 | Zelton Dave Sharp | Inhibition of mammalian target of rapamycin |
DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
CN102612564B (zh) | 2009-04-10 | 2015-08-26 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
CA2794196A1 (en) | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
ES2372077B2 (es) * | 2010-06-24 | 2012-05-18 | Universidad De Sevilla | Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down. |
EP2446886A1 (en) * | 2010-10-29 | 2012-05-02 | Fondazione Telethon | Autophagy regulators and the uses thereof in the treatment of collagen VI defective Muscular Dystrophies |
SG10201600912SA (en) | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
WO2014059295A1 (en) | 2012-10-12 | 2014-04-17 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
ES2900426T3 (es) | 2013-12-31 | 2022-03-16 | Rapamycin Holdings Llc | Preparaciones orales y uso de nanopartículas de rapamicina |
CA2968049A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
GB2538747B (en) * | 2015-05-27 | 2022-04-13 | Airbus Operations Ltd | A measuring apparatus for measuring properties of a surface |
UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
CA3042706A1 (en) | 2016-11-09 | 2018-05-17 | Intrexon Corporation | Frataxin expression constructs |
US20210154372A1 (en) | 2017-05-15 | 2021-05-27 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
WO2020076738A2 (en) * | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
US11541152B2 (en) | 2018-11-14 | 2023-01-03 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
EP3952937A1 (en) | 2019-04-08 | 2022-02-16 | Bard Peripheral Vascular, Inc. | Medical device with drug-eluting coating on modified device surface |
WO2022020522A2 (en) * | 2020-07-21 | 2022-01-27 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
CN115944629A (zh) * | 2022-01-27 | 2023-04-11 | 中以海德人工智能药物研发股份有限公司 | 雷帕霉素在治疗或预防乙型肝炎中的应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1445742A1 (de) * | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
DE1545824A1 (de) | 1965-06-21 | 1969-12-11 | Bayer Ag | Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen |
CA930734A (en) * | 1969-08-11 | 1973-07-24 | Bickel Hans | Antibiotically active rifamycin compounds and processes for their manufacture |
US3686238A (en) * | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
US3900465A (en) * | 1973-04-05 | 1975-08-19 | Lepetit Spa | 3-formylrifamycin azines |
US3905981A (en) * | 1973-10-12 | 1975-09-16 | Research Corp | N-dealkylation of tertiary amines |
US4127720A (en) * | 1977-09-21 | 1978-11-28 | Bristol-Myers Company | Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity |
JPH0262875A (ja) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
WO1991019495A1 (en) | 1990-06-11 | 1991-12-26 | Fujisawa Pharmaceutical Co., Ltd. | Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease |
DE4021404A1 (de) | 1990-07-05 | 1992-01-09 | Sandoz Ag | Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
GB2249027A (en) | 1990-10-23 | 1992-04-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds for hepatic failure |
WO1992013862A1 (en) | 1991-02-05 | 1992-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Lactone compounds |
US5604294A (en) * | 1991-09-05 | 1997-02-18 | Luly; Jay R. | Macrocyclic immunomodulators |
DE69232630T2 (de) | 1991-09-05 | 2003-10-09 | Abbott Lab | Makrocyclische immunmodulatoren |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US7279561B1 (en) * | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
AU686629B2 (en) | 1993-04-23 | 1998-02-12 | Wyeth | Rapamycin Conjugates and Antibodies |
US5798355A (en) * | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
US5525610A (en) * | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
TW427904B (en) * | 1995-12-07 | 2001-04-01 | American Home Prod | Neuroprotective agents |
US5717092A (en) * | 1996-03-29 | 1998-02-10 | Vertex Pharmaceuticals Inc. | Compounds with improved multi-drug resistance activity |
US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
US6187784B1 (en) * | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
AU761083B2 (en) | 1998-06-03 | 2003-05-29 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
AU5487499A (en) | 1998-08-17 | 2000-03-06 | American Home Products Corporation | Photocyclized rapamycins |
US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
WO2000034239A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6441017B1 (en) | 1999-09-09 | 2002-08-27 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6569867B2 (en) * | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
US6670168B1 (en) | 1999-10-29 | 2003-12-30 | Kosan Bioscience, Inc. | Recombinant Streptomyces hygroscopicus host cells that produce 17-desmethylrapamycin |
EP1282626A2 (en) | 2000-05-17 | 2003-02-12 | Kosan Biosciences, Inc. | Polyketide derivatives |
ES2246409T3 (es) | 2001-08-22 | 2006-02-16 | Wyeth | 29-enoles de rapamicina. |
CN1545512A (zh) | 2001-08-22 | 2004-11-10 | 惠氏公司 | 雷帕霉素二醛化合物 |
JP2005532809A (ja) | 2002-07-16 | 2005-11-04 | バイオチカ テクノロジー リミテッド | ポリケチド、及び他の天然物の製造 |
DE102004049700B4 (de) | 2004-10-12 | 2007-10-18 | Aircabin Gmbh | Kraftunterstützungsvorrichtung mit lastabhängiger Kraftunterstützung |
ES2380779T3 (es) | 2004-12-20 | 2012-05-18 | Wyeth Llc | Análogos de rapamicina y usos de los mismos en el tratamiento de trastornos neurológicos, proliferativos e inflamatorios |
MX2007007409A (es) | 2004-12-20 | 2007-07-12 | Wyeth Corp | Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos. |
CA2643350A1 (en) | 2006-03-07 | 2007-09-13 | Wyeth | Meridamycin analogues for the treatment of neurodegenerative disorders |
-
2005
- 2005-12-15 ES ES05849447T patent/ES2380779T3/es active Active
- 2005-12-15 AT AT05849447T patent/ATE549342T1/de active
- 2005-12-15 PE PE2005001466A patent/PE20060765A1/es not_active Application Discontinuation
- 2005-12-15 WO PCT/US2005/045551 patent/WO2006068932A2/en active Application Filing
- 2005-12-15 TW TW094144448A patent/TW200628152A/zh unknown
- 2005-12-15 US US11/300,839 patent/US7276498B2/en not_active Expired - Fee Related
- 2005-12-15 AU AU2005319454A patent/AU2005319454B2/en not_active Expired - Fee Related
- 2005-12-15 CA CA002590155A patent/CA2590155A1/en not_active Abandoned
- 2005-12-15 GT GT200500368A patent/GT200500368A/es unknown
- 2005-12-15 DK DK05849447.7T patent/DK1828202T3/da active
- 2005-12-15 MX MX2007007408A patent/MX2007007408A/es active IP Right Grant
- 2005-12-15 NZ NZ574663A patent/NZ574663A/en not_active IP Right Cessation
- 2005-12-15 BR BRPI0519495-4A patent/BRPI0519495A2/pt not_active IP Right Cessation
- 2005-12-15 RU RU2007119584/04A patent/RU2394036C2/ru not_active IP Right Cessation
- 2005-12-15 SG SG200908383-3A patent/SG158143A1/en unknown
- 2005-12-15 HN HN2005035605A patent/HN2005035605A/es unknown
- 2005-12-15 CN CN2005800437154A patent/CN101084227B/zh not_active Expired - Fee Related
- 2005-12-15 JP JP2007546925A patent/JP5094406B2/ja not_active Expired - Fee Related
- 2005-12-15 KR KR1020077013082A patent/KR20070090913A/ko not_active Application Discontinuation
- 2005-12-15 EP EP05849447A patent/EP1828202B1/en not_active Not-in-force
- 2005-12-15 UA UAA200706849A patent/UA94034C2/ru unknown
- 2005-12-15 AR ARP050105290A patent/AR052269A1/es not_active Application Discontinuation
-
2007
- 2007-01-26 US US11/698,504 patent/US7560457B2/en not_active Expired - Fee Related
- 2007-05-24 CR CR9148A patent/CR9148A/es not_active Application Discontinuation
- 2007-05-25 NO NO20072664A patent/NO20072664L/no not_active Application Discontinuation
- 2007-06-04 IL IL183664A patent/IL183664A/en not_active IP Right Cessation
- 2007-06-18 NI NI200700157A patent/NI200700157A/es unknown
- 2007-08-14 US US11/893,090 patent/US7470682B2/en not_active Expired - Fee Related
-
2008
- 2008-03-04 HK HK08102453.8A patent/HK1108442A1/xx not_active IP Right Cessation
- 2008-11-24 US US12/276,668 patent/US20090203682A1/en not_active Abandoned
-
2009
- 2009-06-09 US US12/481,211 patent/US7795252B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE549342T1 (de) | Rapamycinanaloge und deren verwendungen bei der behandlung proliferativer, entzündlicher und neurologischer störungen | |
IL183772A0 (en) | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | |
DE602006021323D1 (de) | Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen | |
IL183827A0 (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
CR8642A (es) | Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos | |
IL179508A0 (en) | 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
IS8418A (is) | 1,4-tvíútskiptar ísókínílónafleiður sem RAF-kínasatálmar sem eru gagnlegar til að meðhöndla fjölgunarsjúkdóma | |
ATE474578T1 (de) | Verwendung von flibanserin bei der behandlung von prämenstruellen störungen | |
ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
IL177772A0 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
IL180187A0 (en) | Compositions and methods for treating inflammatory disorders | |
EP1893216A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
PL1761266T3 (pl) | Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry | |
IL181706A0 (en) | The treatment of inflammatory disorders and pain | |
IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
SI1831227T1 (sl) | Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj | |
BRPI0714307A2 (pt) | Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos | |
ATE446757T1 (de) | 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen | |
JP2009543796A5 (ja) | 神経学的障害を処置することおよび認知身体能力を強化することにおけるソレノプシンに関する組成物および方法ならびにその使用 | |
HK1101674A1 (en) | Composition for the prevention and treatment of allergic inflammatory disease | |
DE112005001443T5 (de) | Mittel gegen Tuberkulose zur Behandlung und Prophylaxe | |
ZA200801548B (en) | Pyridine derivatives and their use in the treatment of psychotic disorders | |
GB0513413D0 (en) | The treatment of inflammatory disorders and pain | |
GB0406016D0 (en) | The treatment of inflammatory disorders | |
GB0422880D0 (en) | The treatment of inflammatory disorders |